AU2015240094B2 - Combinations of cancer therapeutics - Google Patents

Combinations of cancer therapeutics Download PDF

Info

Publication number
AU2015240094B2
AU2015240094B2 AU2015240094A AU2015240094A AU2015240094B2 AU 2015240094 B2 AU2015240094 B2 AU 2015240094B2 AU 2015240094 A AU2015240094 A AU 2015240094A AU 2015240094 A AU2015240094 A AU 2015240094A AU 2015240094 B2 AU2015240094 B2 AU 2015240094B2
Authority
AU
Australia
Prior art keywords
compound
physiologically acceptable
cancer
acceptable salt
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015240094A
Other languages
English (en)
Other versions
AU2015240094A1 (en
Inventor
Bayard R. Huck
Remigiusz KALETA
Andreas Machl
Erik WILKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2015240094A1 publication Critical patent/AU2015240094A1/en
Application granted granted Critical
Publication of AU2015240094B2 publication Critical patent/AU2015240094B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015240094A 2014-04-03 2015-03-09 Combinations of cancer therapeutics Active AU2015240094B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974765P 2014-04-03 2014-04-03
US61/974,765 2014-04-03
PCT/EP2015/000525 WO2015149909A1 (en) 2014-04-03 2015-03-09 Combinations of cancer therapeutics

Publications (2)

Publication Number Publication Date
AU2015240094A1 AU2015240094A1 (en) 2016-11-17
AU2015240094B2 true AU2015240094B2 (en) 2020-07-30

Family

ID=52692591

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015240094A Active AU2015240094B2 (en) 2014-04-03 2015-03-09 Combinations of cancer therapeutics

Country Status (15)

Country Link
US (1) US9980966B2 (OSRAM)
EP (1) EP3125935B1 (OSRAM)
JP (1) JP6629753B2 (OSRAM)
KR (1) KR102410696B1 (OSRAM)
CN (1) CN106456752B (OSRAM)
AR (1) AR099931A1 (OSRAM)
AU (1) AU2015240094B2 (OSRAM)
CA (1) CA2944573C (OSRAM)
ES (1) ES2768900T3 (OSRAM)
IL (1) IL248126A0 (OSRAM)
MX (1) MX370540B (OSRAM)
NZ (1) NZ725361A (OSRAM)
RU (1) RU2733401C2 (OSRAM)
SG (1) SG11201608189WA (OSRAM)
WO (1) WO2015149909A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021376892A1 (en) * 2020-11-16 2023-06-29 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
WO2025168601A1 (en) * 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012069146A1 (en) * 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
CN100412066C (zh) 2003-09-30 2008-08-20 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
EP1678168B1 (en) 2003-10-24 2012-07-11 Exelixis, Inc. P70s6 kinase modulators and method of use
WO2005054237A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
ATE447957T1 (de) 2003-12-09 2009-11-15 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
ATE543821T1 (de) 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
CN101300029A (zh) * 2005-11-04 2008-11-05 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2010093419A1 (en) 2009-02-11 2010-08-19 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
US9458134B2 (en) * 2013-03-11 2016-10-04 Merck Patent Gmbh Heterocycles as modulators of kinase activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012069146A1 (en) * 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines

Also Published As

Publication number Publication date
CN106456752A (zh) 2017-02-22
US20170100402A1 (en) 2017-04-13
CA2944573A1 (en) 2015-10-08
BR112016020135A8 (pt) 2021-07-06
CN106456752B (zh) 2020-11-20
US9980966B2 (en) 2018-05-29
JP6629753B2 (ja) 2020-01-15
EP3125935A1 (en) 2017-02-08
ES2768900T3 (es) 2020-06-24
BR112016020135A2 (pt) 2017-08-15
MX370540B (es) 2019-12-17
SG11201608189WA (en) 2016-10-28
KR102410696B1 (ko) 2022-06-17
KR20160133005A (ko) 2016-11-21
JP2017509683A (ja) 2017-04-06
EP3125935B1 (en) 2019-10-23
RU2016143153A3 (OSRAM) 2018-10-17
MX2016012825A (es) 2017-01-05
CA2944573C (en) 2022-10-25
WO2015149909A1 (en) 2015-10-08
NZ725361A (en) 2022-09-30
IL248126A0 (en) 2016-11-30
AR099931A1 (es) 2016-08-31
RU2016143153A (ru) 2018-05-04
AU2015240094A1 (en) 2016-11-17
RU2733401C2 (ru) 2020-10-01

Similar Documents

Publication Publication Date Title
KR102635885B1 (ko) Tlr7/8 안타고니스트 및 이의 용도
CN107872977A (zh) Irak4抑制剂与btk抑制剂的组合产品
CA3144985A1 (en) Hdac6-activated macrophages, compositions, and uses thereof
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
AU2015240094B2 (en) Combinations of cancer therapeutics
CA3109184A1 (en) Treatment of b cell malignancies
US20230405118A1 (en) Stat-activated macrophages, compositions, and uses thereof
US11684672B2 (en) Combinations of copanlisib with anti-PD-1 antibody
US20230301981A1 (en) Tlr7/8 antagonists and uses thereof
BR112016020135B1 (pt) Mistura de compostos, seus usos, composição farmacêutica, e conjunto (kit)
US20240382495A1 (en) Combinations of copanlisib with anti-pd-1 antibody
RU2818954C1 (ru) Производные пиридопиримидинона и их использование в качестве модуляторов рецептора ароматических углеводородов
US20230248695A1 (en) Combinations of cancer therapeutics
US20240024324A1 (en) Kinase inhibitor combinations for cancer treatment
WO2021260443A1 (en) Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)